Scientists at VIB-KU Leuven have identified a new mechanism that impacts tumour growth.
The typical lack of oxygen in tumours doesn't only stimulate proliferation, but also offsets the important role of the protein PHD2 as 'cancer cell killer'.
A possible solution lies in blocking the enzyme PP2A/B55, which restores the function of PHD2 and consequently slows down cancer growth.
The research, led by prof Massimiliano Mazzone (VIB-KU Leuven), is published in the leading scientific journal Cell Reports.
Poor prognosis in cancer is typically correlated with hypoxia, a disturbance in the oxygen supply to the tumour cells.
The protein PHD2 is known as a 'hypoxic sensor', as its function is highly dependent on the amount of oxygen.
In the VIB-KU Leuven Center for Cancer Biology, Dr Giusy Di Conza and colleagues, led by prof Massimiliano Mazzone, focused on the phosphorylation -- the addition of a phosphate group -- of this protein.
Interfering in phosphorylation process
When phosphorylated, PHD2 is more active, promoting the death of cancer cells in the low-oxygen areas of the tumour.
However, tumours tend to overexpress the phosphatase PP2A/B55, an enzyme that removes the phosphate group ('dephosphorylation') from PHD2.
As a result, PHD2 is partially inactivated, which offsets the positive effects of this 'cancer cell killer'.
Prof Massimiliano Mazzone (VIB-KU Leuven): "Surprisingly, we found that the phosphorylation status of PHD2 is regulated by pathways such as mTOR, which in tumour and normal cells represents the main sensor of metabolic stresses such as lack of nutrients or growth factors.
This means that our findings might be applied not only to cancer but also to other diseases, such inflammatory or metabolic diseases."
Phosphatase as a cancer target
During the research, prof Mazzone's lab collaborated closely with several domestic and foreign researchers.
In particular, the German ISAS lab (Dortmund) and the Leuven University Hospital played decisive roles, with the latter providing the human cancer samples necessary for the research.
In these samples, the researchers discovered high expressions of PP2A/B55 in tumours compared to healthy tissues.
Prof Massimiliano Mazzone (VIB-KU Leuven): "This leads us to the conclusion that PP2A/B55 is a promising potential target for cancer therapy. That is why we started working together with an interested partner to study the potential of specific drugs against PP2A/B55. The ultimate goal is to design molecules that block the function of this phosphatase, thereby fighting cancer in a targeted way."
Assessing the effects of future drugs
On top of new cancer treatment perspectives, these findings may also lead to new biomarkers: the phosphorylation status of PHD2 might be instrumental to understanding a tumours' transformation process and, consequently, to select the appropriate treatment.
Prof Massimiliano Mazzone (VIB-KU Leuven): "To fully understand all the ins and outs of these processes, we also need to take a closer look at the tumour microenvironment and the immune system. After all, they strongly impact tumour growth. As we speak, we are defining the role of PP2A/B55 in both the tumour microenviroment and in immune cells. In this way, we hope to assess the effects of future drugs that inhibit PP2A/B55.”
(22 Mar 2017)
(22 Mar 2017)